North America Anticoagulation Therapy Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Published Report
  • Jul 2019
  • North America
  • 350 Pages
  • No of Tables: 118
  • No of Figures: 27

North America Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico). – Industry Trends and Forecast to 2026

Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).

North America anticoagulation therapy market is projected to register a substantial CAGR in the forecast period 2019 to 2026.

Segmentation: North America Anticoagulation Therapy Market

North America anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.

  • On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
  • On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others
  • On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others
  • On the basis of route of administration, the market is segmented into oral and injectable
  • On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
  • On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
  • On the basis of type, the market is segmented into generics and branded
  • On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy

Competitive Analysis: North America Anticoagulation Therapy Market

Some of the major players operating in the North America anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical(Group)Co., Ltd. , Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.

Recent Developments

  • In May 2019, Pfizer Inc. received the FDA Approval for Fragmin. It is a first approval for anticoagulant to treat pediatric patients from potentially lifethreatening blood clots. This approval will help company to grow its anticoagulant portfolio and will help to lead the market in anticoagulant therapy as it is first of its kind.

  • In March 2019, Janssen Pharmaceuticals, Inc. subsidiary of Johnson & Johnson Service, Inc. published real world metaanalysis for 95 studies during investigation of non-vitamin K antagonist oral anticoagulants (NOACs) usage and highlighted that it’s NOACs XARELTO, usage lowered the chances of ischemic stroke and intracranial hemorrhage (ICH) as compared to warfarin usage. This will help to grow company’s revenue.
  • In October 2018, Bayer Ag received U.S. Food and Drug Administration (FDA) approval for Xarelto. It is administrated in the order to reduce the chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD). This approval will help the company to develop anticoagulant business in the U.S.

Research Methodology: North America Anticoagulation Therapy Market

Primary Rependants:

Key Opinion Leaders (KOL’s): Manufacturers, Researchers, Distributors, Bakers and Food Industrialists.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and National Sales Managers.


SKU-

TABLE 1 AGEING WORLD POPULATION

TABLE 2 POSTOPERATIVE PULMONARY EMBOLISM OR DEEP VEIN THROMBOSIS IN HIP AND KNEE SURGERIES, 2015

TABLE 3 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 4 NORTH AMERICA DEEP VEIN THROMBOSIS (DVT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 5 NORTH AMERICA PULMONARY EMBOLISM (PE) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 6 NORTH AMERICA ARTERIAL THROMBOEMBOLISM (AT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 7 NORTH AMERICA STROKE IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 8 NORTH AMERICA OTHERS IN NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 9 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 10 NORTH AMERICA NOVEL ORAL ANTICOAGUALTANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 12 NORTH AMERICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 NORTH AMERICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 14 NORTH AMERICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 NORTH AMERICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 16 NORTH AMERICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 18 NORTH AMERICA BIVALIRUDIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 NORTH AMERICA DABIGATRAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 NORTH AMERICA EDOXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 21 NORTH AMERICA BETRIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 NORTH AMERICA RIVAROXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 23 NORTH AMERICA APIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 NORTH AMERICA ENOXAPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 25 NORTH AMERICA DALTEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 26 NORTH AMERICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 27 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION , 2017-2026 (USD MILLION)

TABLE 28 NORTH AMERICA ORAL IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 29 NORTH AMERICA INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 30 NORTH AMERICA INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 31 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 32 NORTH AMERICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 33 NORTH AMERICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 34 NORTH AMERICA ONCOLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 35 NORTH AMERICA RESPIRATORY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 36 NORTH AMERICA NEPHROLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 37 NORTH AMERICA CNS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 38 NORTH AMERICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 39 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 40 NORTH AMERICA PRE-SURGICAL PROCEDURES IN NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 41 NORTH AMERICA POST-SURGICAL PROCEDURES IN NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 42 NORTH AMERICA KIDNEY DIALYSIS IN NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 43 NORTH AMERICA HEART VALVE REPLACEMENT IN NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 44 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 45 NORTH AMERICA GENERICS IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 46 NORTH AMERICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 47 NORTH AMERICA BRANDED IN NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 48 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 49 NORTH AMERICA HOSPITALS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 50 NORTH AMERICA CLINICS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 51 NORTH AMERICA HOMECARE IN ANTICOAGULATION THERAPY MARKET,BY REGION, 2017-2026 (USD MILLION)

TABLE 52 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 53 NORTH AMERICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 54 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 55 NORTH AMERICA HOSPITAL PHARMACY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 56 RETAIL PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 57 NORTH AMERICA ONLINE PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 58 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 59 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 60 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 61 NORTH AMERICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 62 NORTH AMERICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 63 NORTH AMERICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 64 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 65 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 66 NORTH AMERICA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 67 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 68 NORTH AMERICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 69 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 70 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 71 NORTH AMERICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 72 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 73 NORTH AMERICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 74 U.S. ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 75 U.S. ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 76 U.S. NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 77 U.S. HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 78 U.S. VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 79 U.S. ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 80 U.S. ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 81 U.S. INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 82 U.S.ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 83 U.S. CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 84 U.S. ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 85 U.S. ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 86 U.S. BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 87 U.S. ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 88 U.S. ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 89 CANADA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 90 CANADA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 91 CANADA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 92 CANADA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 93 CANADA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 94 CANADA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 95 CANADA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 96 CANADA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 97 CANADA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 98 CANADA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 99 CANADA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 100 CANADA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 101 CANADA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 102 CANADA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 103 CANADA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 104 MEXICO ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 105 MEXICO ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 106 MEXICO NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 107 MEXICO HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 108 MEXICO VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 109 MEXICO ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 110 MEXICO ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 111 MEXICO INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 112 MEXICO ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 113 MEXICO CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 114 MEXICO ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 115 MEXICO ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 116 MEXICO BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 117 MEXICO ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 118 MEXICO ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions